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Abstract
Bacteraemia due to carbapenemase-producing Enterobacteriaceae is an emerging medical problem. Management of this entity is
complicated by the difﬁculty in identifying resistance patterns and the limited therapeutic options. A cohort study was performed including
all episodes of bloodstream infection due to OXA-48-producing Enterobacteriaceae (O48PE), occurring between July 2010 and April 2012.
Data on predisposing factors, clinical presentation, therapy and outcome were collected from medical records. There were 40 cases of
bacteraemia caused by O48PE, 35 Klebsiella pneumoniae and ﬁve Escherichia coli. Patients were elderly with signiﬁcant comorbidities (57.5%
underlying malignancy). Thirty-ﬁve cases (87.5%) were nosocomial, and ﬁve (12.5%) were healthcare-associated. Patients had frequently
been exposed to antibiotics and to invasive procedures during hospitalization. The most common source of bacteraemia was the urinary
tract followed by deep intra-abdominal surgical site infection. Clinical presentation was severe sepsis or shock in 18 cases (45%). Extended-
spectrum b-lactamase production was detected in 92.5% of isolates. MIC90 for ertapenem, imipenem and meropenem were 32, 16 and
16 mg/L, respectively. Most frequently preserved antibiotics were amikacin, colistin, tigecycline and fosfomycin. These antibiotics combined
are the basis of targeted therapies, including carbapenem in selected cases. Median delay in starting clinically adequate and microbiologically
appropriate treatment was 3 days. Crude mortality during admission and within 30 days from bacteraemia was 65% and 50%, respectively.
Bloodstream infections caused by O48PE have a poor prognosis. Delay in diagnosis and in initiation of optimal antimicrobial therapy is
frequent. Suspicion and rapid identiﬁcation could contribute to improving outcomes.
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Introduction
The emergence of carbapenem resistance among Enterobac-
teriaceae has been increasingly reported and is now a matter
of major clinical concern [1–3]. OXA-48, a carbapenem-
hydrolysing class D b-lactamase is one of the several carba-
penemases that have been described so far [1,4]. This
carbapenemase is encoded by the blaOXA-48 gene, which is
part of the Tn1999 composite transposon made of two copies
of the insertion sequence IS1999 [5].
OXA-48-producing isolates are frequently multidrug-resis-
tant, because they combine multiple resistance mechanisms.
This enzyme shows different hydrolysing activities against
b-lactam antibiotics, with high activity against penicillins but only
low activity against carbapenems. OXA-48 carbapenemase has
very weak activity against third-generation and fourth-genera-
tion cephalosporins; however, these are seldom a therapeutic
option because other b-lactamases, such as extended-spectrum
b-lactamases (ESBL), are frequently associated [1].
The high prevalence of infections caused by OXA-48
producers in Turkey is well established [5,6], as it was ﬁrst
identiﬁed in a Klebsiella pneumoniae clinical isolate in 2001 [7].
From the Middle East (Turkey and Lebanon) and Northern
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Africa, OXA-48 is spreading into Europe (France, Belgium,
Germany, Spain) and elsewhere [1]. All previously described
series of O48PE infections were found in hospital settings, and
most of them were involved in nosocomial outbreaks [8,9].
The aim of this report is to describe the epidemiological,
microbiological and clinical features of adult patients with
OXA-48-producing Enterobacteriaceae (O48PE) bloodstream
infections (BSI) occurring in the setting of a large outbreak in a
Spanish Hospital.
Patients and Methods
Setting and design
Hospital La Paz is a 1328-bed university-afﬁliated hospital
providing acute care for a population of 600 000 in Madrid,
Spain. In December 2010 an outbreak of OXA-48-producing
K. pneumoniae was ﬁrst identiﬁed in our hospital; this
prompted us to set up a prospective observational study with
the aim of including all consecutive episodes of bacteraemia
due to O48PE. The study period was from July 2010 to April
2012. Cases were detected through the daily review of blood
culture results in adult patients (aged >18 years). Phenotyp-
ically similar isolates (those showing an ESBL phenotype and
high resistance to amoxicillin/clavulanic acid and piperacillin/
tazobactam combined) stored at the microbiology laboratory
were retrospectively evaluated for the presence of OXA-48,
and one additional case of BSI due to O48PE was detected and
included in our series. The study was approved by the local
ethics committee.
Variables and data collection
We systematically collected from medical records demo-
graphic characteristics, underlying diseases, reason for admis-
sion, ﬁnal diagnosis, source of bacteraemia, antimicrobial
therapy and outcome. Antibiotic exposure preceding BSI
(previous 30 days) was measured as deﬁned daily dose (DDD);
the DDD was deﬁned by the WHO/ATC index (available at
http://www.whocc.no).
Deﬁnitions
Bloodstream infections were primarily classiﬁed as nosocomial
or community-acquired, in accordance with the classic CDC
criteria [10]. Episodes of community-acquired bacteraemia,
were further classiﬁed as healthcare-associated (HCA) if any of
the following criteria were present [11]: 48-h hospital
admission during the previous 90 days, receipt of haemodial-
ysis, intravenous medication or home wound care in the
previous 30 days, and residence in a nursing home or long-
term care facility.
Charlson comorbidity index (range 0–37) [12] and McCa-
be–Jackson classiﬁcation (non-fatal, ultimately fatal or rapidly
fatal) [13] were used to evaluate comorbidity and prognosis.
Acute severity of illness was evaluated with the use of the Pitt
Bacteraemia Score [14]. In accordance with the criteria of
systemic inﬂammatory response syndrome sepsis level was
graded as sepsis, severe sepsis or septic shock [15].
The source of bacteraemia was determined according to
the clinical presentation or by the evidence of an identical
strain cultured near to, or on the same date as the onset of BSI
from other body sites. If the source of bacteraemia could not
be identiﬁed, it was classiﬁed as primary bacteraemia.
Antimicrobial therapy was considered microbiologically
appropriate if the patient received one active agent against
the isolate (MIC within the susceptible range), and clinically
adequate if the patient received a combination of two active
antibiotics, at the right dose (including loading dose and
adjusted to renal function when necessary) and route accord-
ing to the source of infection. Use of imipenem or meropenem
if MIC was <4 mg/L was considered adequate if high-dosed and
associated with a second microbiologically active agent [3,16].
Outcome parameters
Crude mortality during hospitalization and within 30 days after
clinical onset of BSI episode was analysed. Relationship
between death and BSI episode (directly related, indirectly
related and non-related) was established by two different
investigators by reviewing hospital medical records. In those
patients who had been discharged, mortality was evaluated
through HORUS, the regional electronic health records
system, which includes data from primary care. Readmission
within 1 month after discharge and its relatedness to the
previous episode of bacteraemia were also collected as
indicators of patient outcome.
Microbiological studies
Blood cultures were incubated in the Bactec automated blood
culture device (BACTEC; Becton Dickinson, Franklin Lakes,
NJ, USA) and BacT/ALERT® (BioMerieux, Marcy l’Etoile,
France) blood culture bottle systems. All positive blood
cultures were routinely subcultivated on three agar plates
(Becton-Dickinson): sheep blood agar, chocolate blood agar
and Brucella blood agar.
Identiﬁcation was done using MALDI Biotyper (Bruker
Daltonik GmbH, Bremen, Germany) and antimicrobial suscep-
tibility testing was performed using the automated system
(Vitek2®; BioMerieux). All Enterobacteriaceae isolates
retrieved from blood cultures having MIC >1 mg/L to imip-
enem or  0.5 mg/L to ertapenem, according to the CLSI
guidelines [17], were studied to rule out the production of
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carbapenemase with a modiﬁed Hodge test. Carbapenem MIC
was conﬁrmed by E-test (BioMerieux); colistin and fosfomycin
MICs were also tested by E-test. Tigecycline MICs were
evaluated according to the interpretative criteria of the US
Food and Drug Administration. Although Vitek2® is able to
detect ESBL production, this was later conﬁrmed by E-test
ESBL stripes (BioMerieux).
As part of the microbiology laboratory work for identiﬁ-
cation of isolates, polymerase chain reaction ampliﬁcation was
used for the detection of the blaOXA-48 gene (using speciﬁc
primers for OXA-48 and the insertion sequence IS1999 of the
Tn1999 transposon [18]) and for the detection of other
carbapenemase genes blaKPC, blaVIM, blaIMP, blaNDM-1 and
b-lactamase-encoding ESBL genes blaTEM, blaSHV, blaOXA-1
and blaCTX-M [19]. Polymerase chain reaction ampliﬁcation
products were sequenced using the dideoxynucleotide chain
termination method.
As these infections were part of a hospital-wide outbreak,
clonal relationships between strains were studied using the
DiversiLab® (DL) System (BioMerieux) [20]. Multilocus
sequence typing based on the gapA, infB, mdh, pgi, phoE, rpoB
and tonB geneswas performed on allK. pneumoniae isolates [21].
Statistical analysis
Continuous variables were compared using the Mann–Whit-
ney U test. Categorical variables were compared using the
chi-square test or Fisher’s Exact test, as appropriate. Statistical
software program SPSS, version 17.0 for Windows (SPSS,
Chicago, IL, USA) was used to perform all analyses.
Results
Clinical and epidemiological characteristics
During the study period, 40 patients with bacteraemia caused
by O48PE (35 K. pneumoniae and ﬁve Escherichia coli), were
detected and included (Table 1). Patients were elderly, with a
mean age of 70 years (median 73, range 38–92) and predom-
inantly male (57.5%). Comorbid conditions were frequent,
with a median Charlson Index of 5 (range 0–11), and a high
proportion of underlying malignancies (57.5%), including 12
patients (30%) with haematological malignancies.
No community-acquired cases were detected. Thirty-ﬁve
(87.5%) cases were nosocomial; ﬁve cases (12.5%) were HCA
(all of them had previous hospitalization at our institution).
Each patient had a single episode of bacteraemia. At the time
when BSI occurred, 17 (48.6%) of the 35 patients with
nosocomially acquired disease were hospitalized in a medical
service, ten (28.6%) were in a surgical service, and eight
(22.8%) were in intensive care units. The median duration of
hospital stay before onset of BSI in nosocomially acquired
cases was 46.6 days (range 2–188 days).
During the hospital stay before the BSI episode, invasive
procedures were frequent. Twenty-four patients (60%) had at
least one surgery. Eight patients (20%) had a central venous
catheter and 11 (27.5%) had a urinary catheter when BSI
occurred.
Antibiotic exposure preceding BSI was high, with a median
antibiotic DDD of 39.9 (range 0–251) for any antibiotic, 10.5
(range 0–105.2) for b-lactams (excluding carbapenems), 3.5
(range 0–135) for carbapenems and 0 (range 0–67.2) for
quinolones.
The most common source of bacteraemia was the urinary
tract, found in 12 patients (30%), followed by deep intra-
abdominal surgical site infections in ten (25%) patients, primary
bacteraemia in seven (17.5%) patients and catheter-related
bacteraemia in four (10%) patients.
Regarding severity of disease, 11 patients with O48PE BSI
(27.5%) presented as septic shock, seven as severe sepsis
(17.5%) and nine as sepsis (22.5%); median Pitt score was 2
(range 0–11).
Microbiological results
All of the isolates included in the study were positive for
blaOXA-48 and negative for other carbapenemases. Susceptibil-
ities of OXA-48-producing K. pneumoniae isolates to antimi-
crobials are shown in Table 2. All of the isolates showed a high
level of resistance to amoxicillin-clavulanate and piperacillin-
tazobactam. Production of ESBL was detected in 36 (90%)
isolates, and all non-ESBL-producing isolates were E. coli. Using
DiversiLab® eight different clones were detected. The majority
of ESBLs belonged to clone 1, which has been deﬁned as
sequence type (ST) 405, carrying CTX-M-15, as previously
described [22]. Values of MIC50 for ertapenem, imipenem and
meropenem were 16 (range 2 to >32), 4 (range 0.5 to >32)
and 2 mg/L (range 1 to >32), respectively. Except for non-ESBL
producers, which remained susceptible, the majority of the
isolates were resistant to third-generation and fourth-gener-
ation cephalosporins and aztreonam. The most frequently
preserved antibiotics were amikacin, colistin, tigecycline and
fosfomycin, which remained active in 97.5% (39/40), 87.5% (35/
40), 67.5% (27/40), 52.5% (19/40) of the isolates, respectively.
Treatment
Thirty-four of the 40 (85%) patients received microbiologically
appropriate therapy and 70% were clinically adequately treated
with at least two active antibiotics, at a proper dosage and
route according to the source of infection. Different combi-
nations of amikacin, fosfomycin, colistin, tigecycline and
meropenem were used. Meropenem was chosen in ﬁve cases
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and imipenem in other one, as part of targeted therapy, when
MIC was <4 mg/L, and was prescribed at high doses (2 g/8 h),
adjusted to renal function if needed. In those patients receiving
targeted treatment, the median delay in starting appropriate
and adequate treatment was 3 days (range 0–8).
Outcome analysis
Crude mortality during hospital stay and within 30 days from
onset of BSI was 65% (26/40) and 50% (20/40), respectively.
Kaplan–Meier estimation was used to obtain the 30-day
survival curve (Fig. 1). In 15 of the 26 (57.7%) patients who
died during hospitalization, death was considered directly
related to the BSI episode, based on clinical judgement.
The mean and median hospital stay of these patients after
onset of BSI was 29.2 and 19 days (range 0–152 days),
respectively.
Only two patients were readmitted within 30 days after
hospital discharge for causes related to their previous episode
of bacteraemia. The clinical and demographic features of
patients and therapeutic options used, according to their
outcome, are shown in Table 3. Speciﬁc data about the 34
treated patients are shown in Table 4. In univariate analysis we
did not ﬁnd any clinical or therapeutic factor associated with
improved survival (Tables 3 and 4).
Discussion
There are few data regarding clinical features of infections
caused by O48PE. Previous reports included a limited number
of cases and focused mainly on microbiological and epidemi-
ological features [1,5,8,9,23,24]. Our report, which to the best
of our knowledge is the largest series of BSI caused by O48PE,
provides information on clinical, epidemiological, microbiolog-
ical and therapeutic features in the setting of a large outbreak
occurring in a single centre [22].
O48PE are difﬁcult to detect because a signiﬁcant proportion
of the isolates have carbapenem MICs that fall within or slightly
above the normal range. Indeed, 50% of O48PE isolates included
in this study had meropenem MIC  2 mg/L, and would have
been considered to be within the susceptibility range before the
last update of CLSI cut-off points [17] and current European
Committee for Antibiotic Susceptibility Testing clinical break
points (www.eucast.org). Epidemiological cut-off values of the
European Committee for Antibiotic Susceptibility Testing are of
value in the phenotypic detection of resistance to antimicrobial
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FIG. 1. Kaplan–Meier 30-day survival curve.
TABLE 2. Antimicrobial susceptibility of O48-producing
Klebsiella pneumoniae isolates
MIC (Range) MIC50 MIC90
Amoxicillin/Clavulanate >16/8 >16/8 >16/8
Piperacillin/Tazobactam >64/4 >64/4 >64/4
Cefoxitin  8 to >16  8 >16
Cefotaxime  1 to >8 >8 >8
Cefotaxime/clavulanate  1/4 to >8/4  1/4 >8/4
Ceftazidime  1 to >16 >16 >16
Ceftazidime/clavulanate  1/4 to >8/4  1/4 >8/4
Cefepime  1 to >8 >8 >8
Aztreonam  1 to >8 >8 >8
Ertapenem* 2 to >32 16 > 32
Imipenem* 0.5 to >32 4 16
Meropenem* 1.0 to >32 2 16
Ciproﬂoxacin 1 to >4 >4 >4
Gentamicin 8 to >8 >8 >8
Tobramicin  4 to >8 >8 >8
Amikacin  2 to >16  2 16
Colistin* 0.25 to 24 0.5 4
Tigecycline  0.5 to >8 1 >8
Fosfomycin 8 to >128 128 >128
Trimethoprim/Sulfamethoxazol  2/38 to >4/76 >4/76 >4/76
*E-test results.
TABLE 3. Distribution of clinical and demographical features
and therapeutic options within patients with O48PE blood-
stream infection grouped by clinical outcome
Characteristic
All patients
(n = 40)
Patients alive
at day 30
after onset
of BSI
(n = 20) (%)
Patients dead
at day 30 after
onset of BSI
(n = 20) (%)
Source of infection
Urinary tract 12 6 (30) 6 (30)
Deep intra-abdominal
surgical site infection
10 4 (20) 6 (30)
Primary bloodstream
infection
7 4 (20) 3 (15)
Catheter-related
bloodstream infection
4 4 (20) 0 (0)
Others 7 2 (10) 5 (25)
Previous malignancy 23 10 (50) 13 (65)
Solid neoplasm 11 4 (20) 7 (35)
Haematopoietic malignancy 12 6 (30) 6 (30)
Previous surgery 24 10 (50) 14 (70)
Severity of presentation
Mean Pitt Score 2.62 1.8 3.45
Septic shock 11 4 (20) 7 (35)
Severe sepsis 7 2 (10) 5 (25)
Septic shock or
severe sepsis
18 6 (30) 12 (60)
Antimicrobial therapy
Microbiologically
appropriate therapy
34 19 (95) 15 (75)
Clinically adequate
therapy
27 14 (70) 13 (65)
p value non-signiﬁcant for all comparisons.
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agents as a biological phenomenon and may indicate the
development of resistance at a level below the clinical
breakpoint. To improve identiﬁcation of carbapenem-resistant
enterobacteria, CLSI recommends that production of carba-
penemases should be suspected in enterobacterial isolates with
ertapenem MIC values  0.5 mg/L, or in those with imipenem
or meropenem MIC >1 mg/L [17]. This consideration is also
supported by our data, showing that ertapenem resistance is the
most sensitive indicator of OXA-48 activity, and meropenem
the most frequently preserved carbapenem.
Bloodstream infections caused by O48PE were associated
with a poor prognosis despite the urinary tract being the most
common source of infection in half of the patients. Overall, 30-
day mortality reached 50%. Of note, advanced age, signiﬁcant
comorbidity, active malignancies, long hospital stays and
surgical interventions before the episode of bacteraemia were
very frequent among these patients.
The best therapeutic approach to O48PE BSI is controver-
sial and, in our opinion, selection of the appropriate therapy
should be made on a case-by-case basis, balancing efﬁcacy and
toxicity, as therapeutic options are limited. Although amikacin,
colistin, tigecycline and fosfomycin were the antibiotics that
remained most frequently effective, no single antimicrobial was
uniformly active against O48PE isolates, as it has been
previously reported [25]. Third-generation cephalosporins,
which remained active against OXA-48-producing but ESBL-
negative isolates, have shown good clinical response in one
animal model [26]. Unfortunately, as in our case, ESBLs are
frequently associated with OXA-48, limiting the use of these
agents. The use of carbapenems for the treatment of infections
caused by carbapenemase-producing Enterobacteriaceae, if
either meropenem or imipenem MICs are  4 mg/L, has been
advocated [3]. Nevertheless, several failures of imipenem-
containing regimens to treat infections caused by O48PE have
been reported [6,9].
Although there is no clear evidence in the literature for the
superiority of combination therapy, we, like others, tend to
combine two active agents to treat serious infection such as
BSI [1,27]. In our data, success rate seems to be higher in
patients treated with a single agent treatment, but this ﬁnding
should be interpreted with caution because patients who
received monotherapy were carefully selected for such
treatment because of less severe presentation or an easily
treatable source of infection, mainly urinary tract infections. In
addition to a non-b-lactam antibiotic, we believe that
b-lactams, usually ceftazidime if ESBL-negative, or high-dose
meropenem if MIC is  4 mg/L, should be included as part of
the combined therapy.
Median interval between onset of BSI and initiation of
microbiologically appropriate and clinically adequate antimi-
crobial therapy was 3 days, and could explain, in conjunction
with a baseline-deteriorated patient condition, the high
mortality observed in our series. In another study of BSI
caused by carbapenem-resistant Enterobacteriaceae [28], a
similar delay in the administration of appropriate therapy and a
high mortality rate (40%) have also been reported.
Given the poor prognosis of BSI caused by O48PE,
improvement in early detection and treatment is needed.
Prompt initiation of optimal antimicrobial therapy in infec-
tions caused by carbapenem-resistant enterobacteria could
be achieved if appropriate empirical antimicrobial protocols
are applied in selected epidemiological settings. Patients with
nosocomial infections, especially if they are known to be
colonized by O48PE or other carbapenem-resistant entero-
bacteria, should be empirically treated with a combination of
drugs with activity against these multi-drug-resistant bacteria.
In addition, new methods for rapid detection of carbapen-
emases [29] could be useful to reduce the period of empirical
antimicrobial therapy and to reﬁne the antibiotic regimen
used.
In conclusion, OXA-48 carbapenemase is an emergent
resistance mechanism in Enterobacteriaceae, which can be
involved in nosocomial and HCA bacteraemias. It is important
to suspect and identify this mechanism of resistance, to offer
targeted therapies or to change empirical treatment protocols
in particular cases. Considering the often-unfavourable out-
come, identiﬁcation of carriers and reinforcement of infection
control practices is of critical relevance to avoid the spread of
these bacteria.
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TABLE 4. Outcome of 34 treated patients according to
antimicrobial regimens used
Treatment
All
patients
(n = 34)
Patients alive
at day 30 after
onset of BSI
(n = 19) (%)
Patients dead
at day 30 after
onset of BSI
(n = 15) (%)
Monotherapy
Colistin 1 1 (5.2) 0 (0)
Tigecycline 2 2 (10.5) 0 (0)
Amikacin 3 2 (10.5) 1 (6.6)
Carbapenem 1 0 (0) 1 (6.6)
Total monotherapy 7 5 (26.3) 2 (13.3)
Combined therapy
Two or more active drugs
(carbapenem not included)
21 10 (52.6) 11 (73.3)
Two or more active drugs
(carbapenem included)
6 4 (21.1) 2 (13.3)
Total combined therapy 27 14 (73.7) 13 (86.6)
p value non-signiﬁcant for all comparisons.
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